NeOnc Technologies (NTHI) said Tuesday that its phase 1 trial of NEO212 for the treatment of brain cancer is nearing full enrollment.
The final group is expected to complete the study's dosing protocol, the company said, adding that the NEO212 trial protocol has five escalating groups with three patients per group.
NEO212 is a combination of temozolomide, which is the current standard-of-care chemotherapy for malignant gliomas, and perillyl alcohol, NeOnc said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.